Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results

1. Biogen has decided to discontinue its collaboration with Ionis on treatments for Amyotrophic Lateral Sclerosis (ALS) and Angelman Syndrome.
2. The decision follows early-stage readouts from clinical trials, which did not meet the desired outcomes.
3. Biogen and Ionis have been working together to develop antisense oligonucleotide therapies for these neurological disorders.
4. The treatments aimed to slow down or halt the progression of ALS and Angelman Syndrome, which currently have no cure.
5. Despite the setback, both companies remain committed to advancing research and development in the field of neurological disorders.
6. Biogen will continue to focus on other areas of its pipeline, while Ionis will explore alternative strategies for treating ALS and Angelman Syndrome.